A Phase 1 interventional study of Test formulation of HRS-1893 tablet and Reference formulation of HRS-1893 tablet in Cardiomyopathy, sponsored by Shandong Suncadia Medicine Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Shandong Suncadia Medicine Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Cardiomyopathies with a site in China — 12 open to participants now, 12 under way, 1 of them phase 3. Cardiomyopathies · China.
Among the 25 studies in Cardiomyopathies with a site in China, this one is the 9th largest by enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2026, is one of 4 in phase 1, and was the 22nd registered.
553 studies on the registry are indexed under Cardiomyopathies; 151 are open to participants now.
Browse Cardiomyopathies studies →12 of the 25 studies in Cardiomyopathies with a site in China are open now. Recruiting first, the newest first:
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18+
Chinese Academy of Medical Sciences, Fuwai Hospital · Sites in China
Ages 18+ · Healthy volunteers
Alnylam Pharmaceuticals · Sites in China, United States, Argentina and 33 more countries
Ages 18–85
Guangdong Provincial People's Hospital · Sites in China
Ages 18–85
First Affiliated Hospital Xi'an Jiaotong University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 115 Cardiomyopathies studies recruiting now, 70 (61%) set no upper age limit and 17 (15%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 1 · Phase 3 2 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 58 is above the median of 51 across 266 interventional studies indexed under Cardiomyopathies.
Median enrollment 96 across the 13 interventional studies, 1,000 across the 12 observational. Of the 9 that completed or were terminated, 1 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 25 have an industry lead sponsor. The 10 most frequent:
This study is registered under Shandong Suncadia Medicine Co., Ltd., one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Shandong Suncadia Medicine Co., Ltd. is the lead sponsor of 87 studies on the registry; 39 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 3 studies filed under Cardiomyopathies — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Cardiomyopathies with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will investigate the bioequivalence between two formulations of HRS-1893 tablets. Safety and tolerability will also be assessed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Test formulation of HRS-1893 tablet
Drug: Reference formulation of HRS-1893 tablet
Test formulation of HRS-1893 tablet, oral.
Reference formulation of HRS-1893 tablet, oral.
Peak concentration (Cmax).
Primary Pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Area under the plasma concentration - time curve from Time 0 to the last quantifiable time point (AUC0-t).
Primary Pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Area under the plasma concentration - time curve from Time 0 to infinity (AUC0-∞).
Primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Time to peak concentration (Tmax).
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Elimination half-life (t1/2).
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Apparent clearance (CL/F).
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Apparent volume of distribution (Vz/F).
Other primary pharmacokinetic (PK) parameters of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 17.
Incidence and severity of any adverse events (AEs).
Safety and tolerability of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 21 ± 2.
12-Lead Electrocardiogram (ECG) QT Interval.
Safety and tolerability of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 21 ± 2.
Transthoracic echocardiogram (TTE) results.
Safety and tolerability of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 21 ± 2.
Vital signs results - blood pressure.
Safety and tolerability of different HRS-1893 formulations in healthy subjects.
Time frame: From Day 1 to Day 21 ± 2.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2026 to primary completion in Sep 2026, 5 months.
Of 16 phase 1 interventional studies under Cardiomyopathies, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's 5 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shandong Suncadia Medicine Co., Ltd. →